Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 7/2017

01-07-2017 | Stomach and Duodenum (J Pisegna and J Benhammou, Section Editors)

Pathophysiology of Gastric NETs: Role of Gastrin and Menin

Authors: Sinju Sundaresan, Anthony J. Kang, Juanita L. Merchant

Published in: Current Gastroenterology Reports | Issue 7/2017

Login to get access

Abstract

Purpose of review

Neuroendocrine tumors (NETs) were initially identified as a separate entity in the early 1900s as a unique malignancy that secretes bioactive amines. GI-NETs are the most frequent type and represent a unique subset of NETs, because at least 75% of these tumors represent gastrin stimulation of the enterochromaffin-like cell located in the body of the stomach.
The purpose of this review is to understand the specific role of gastrin in the generation of Gastric NETs (G-NETs).

Recent findings

We review here the origin of enterochromaffin cells gut and the role of hypergastrinemia in gastric enteroendocrine tumorigenesis. We describe generation of the first genetically engineered mouse model of gastrin-driven G-NETs that mimics the human phenotype. The common mechanism observed in both the hypergastrinemic mouse model and human carcinoids is translocation of the cyclin-dependent inhibitor p27kip to the cytoplasm and its subsequent degradation by the proteasome.

Summary

Therapies that block degradation of p27kip, the CCKBR2 gastrin receptor, or gastrin peptide are likely to facilitate treatment.
Literature
1.
Oberndorfer S. Karzinoïde Tumoren des Dunndarms. Frankf Z für Pathol. 1907;1:426–9.
2.
Modlin IM, Shapiro MD, Kidd M, Eick G. Siegfried oberndorfer and the evolution of carcinoid disease. Arch Surg. 2007;142(2):187–97.CrossRefPubMed
3.
•• de Herder WW, Rehfeld JF, Kidd M, Modlin IM. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30(1):3–17. Review of the origin of carcinoids in the GI tract with an emphasis on the historic evolution from the clinical description to WHO designation. CrossRefPubMed
4.
Pearse AG, Polak JM. Neural crest origin of the endocrine polypeptide (APUD) cells of the gastrointestinal tract and pancreas. Gut. 1971;12(10):783–8.CrossRefPubMedPubMedCentral
5.
Pearse AG. The APUD cell concept and its implications in pathology. Pathol Annu. 1974;9(0):27–41.PubMed
6.
Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425(6):547–60.CrossRefPubMed
7.
Moreira RK, Washington K. Pathology of gastrointestinal neuroendocrine tumors: an update. Surg Pathol Clin. 2010;3(2):327–47.CrossRefPubMed
8.
• Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191–205. Review of novel medical, radiologic and surgical treatments. CrossRefPubMed
9.
Scherubl H, Cadiot G, Jensen RT, Rosch T, Stolzel U, Kloppel G. Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems? Endoscopy. 2010;42(8):664–71.CrossRefPubMed
10.
Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRefPubMed
11.
Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Management of gastric and duodenal neuroendocrine tumors. World J Gastroenterol. 2016;22(30):6817–28.CrossRefPubMedPubMedCentral
12.
•• Anlauf M, Perren A, Meyer CL, Schmid S, Saremaslani P, Kruse ML, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology. 2005;128(5):1187–98. Showed that MEN1 gastrinomas arise from precursor lesions within the submucosal of the duodenum. Patients with duodenal gastrinomas are more likely to have the MEN1 mutations and therefore are at a greater risk for developing gastric carcinoids due to the tumor origin of gastrin. CrossRefPubMed
13.
Ooi A, Ota M, Katsuda S, Nakanishi I, Sugawara H, Takahashi I. An unusual case of multiple gastric carcinoids associated with diffuse endocrine cell hyperplasia and parietal cell hypertrophy. Endocr Pathol. 1995;6(3):229–37.CrossRefPubMed
14.
•• Abraham SC, Carney JA, Ooi A, Choti MA, Argani P. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005;29(7):969–75. Overview of a new carcinoid phenotype in which the G-NETs develop in the setting hypergastrinemia and achlorhydria due to non-functional parietal cells. CrossRefPubMed
15.
Walsh JH. Gastrointestinal hormones. In: Johnson LR, Alpers DH, Christensen J, Jacobson ED, Walsh JH, editors. Physiology of the gastrointestinal tract. New York: Raven Press; 1994. p. 1–128.
16.
Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattsson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Gastroenterology. 1990;99:935–42.CrossRefPubMed
17.
Samuelson LC, Isakoff MS, Lacourse KA. Localization of the murine cholecystokinin A and B receptor genes. Mamm Genome. 1995;6(4):242–6.CrossRefPubMed
18.
19.
Minalyan A, Benhammou JN, Artashesyan A, Lewis MS, Pisegna JR. Autoimmune atrophic gastritis: current perspectives. Clin Exp Gastroenterol. 2017;10:19–27.CrossRefPubMedPubMedCentral
20.
Antonodimitrakis P, Tsolakis A, Welin S, Kozlovacki G, Oberg K, Granberg D. Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity? World J Gastroenterol. 2011;17(25):3066–8.CrossRefPubMedPubMedCentral
21.
Vannella L, Lahner E, Annibale B. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol. 2012;18(12):1279–85.CrossRefPubMedPubMedCentral
22.
Lahner E, Esposito G, Pilozzi E, Purchiaroni F, Corleto VD, Di Giulio E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol. 2015;50(7):856–65.CrossRefPubMed
23.
D'Adda T, Keller G, Bordi C, Hofler H. Loss of heterozygosity in 11q13-14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Investig. 1999;79(6):671–7.PubMed
24.
Sano M. Electron microscope study on endocrine cells and tumor cells in the glandular stomach of Praomys (mastomys) natalensis. Arch Histol Jpn. 1975;38(3):237–58.CrossRefPubMed
25.
Tang LH, Modlin IM, Lawton GP, Kidd M, Chinery R. The role of transforming growth factor alpha in the enterochromaffin-like cell tumor autonomy in an African rodent mastomys. Gastroenterology. 1996;111(5):1212–23.CrossRefPubMed
26.
Asahara M, Kinoshita Y, Nakata H, Matsushima Y, Naribayashi Y, Nakamura A, et al. Gastrin receptor genes are expressed in gastric parietal and enterochromaffin-like cells of Mastomys natalensis. Digest Diseases Sci. 1994;39:2149–56.CrossRef
27.
Bilchik AJ, Nilsson O, Modlin IM, Sussman J, Zucker KA, Adrian TE. H2-receptor blockade induces peptide YY and enteroglucagon-secreting gastric carcinoids in mastomys. Surgery. 1989;106(6):1119–26.
28.
Modlin IM, Tang LH, Lawton GP, Darr UM, Zhu ZH, Soroka CJ. Enterochromaffin-like cell pathobiology of mastomys. Ann N Y Acad Sci. 1994;733:365–79.CrossRefPubMed
29.
Shen HC, Ylaya K, Pechhold K, Wilson A, Adem A, Hewitt SM, et al. Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice. Endocrinology. 2010;151(8):4024–30.CrossRefPubMedPubMedCentral
30.
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001;98(3):1118–23.CrossRefPubMedPubMedCentral
31.
Crabtree JS, Scacheri PC, Ward JM, McNally SR, Swain GP, Montagna C, et al. Of mice and MEN1: insulinomas in a conditional mouse knockout. Mol Cell Biol. 2003;23(17):6075–85.CrossRefPubMedPubMedCentral
32.
Biondi CA, Gartside MG, Waring P, Loffler KA, Stark MS, Magnuson MA, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol. 2004;24(8):3125–31.CrossRefPubMedPubMedCentral
33.
Veniaminova NA, Hayes MM, Varney JM, Merchant JL. Conditional deletion of menin results in antral G cell hyperplasia and hypergastrinemia. Am J Physiol Gastrointest Liver Physiol. 2012. Deletion of Men1 alone in mice is not sufficient for GI-NET development.
34.
•• Sundaresan S, Kang AJ, Hayes MM, Choi EK, Merchant JL. Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids. Gut. 2016. First genetically engineered mouse model of G-NETs (carcinoids). The mechanism involved a graded increase in plasma gastrin from menin deletion (transcriptional inhibitor), somatostatin (inhibitor of gastrin gene expression and secretion) and acid suppression with omeprazole (parietal cell atrophy, hypochlorhydria). An essential target identified in both the mouse model and in human tissue was the loss of p27 Kip1 .
35.
Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, et al. The CCK(2) receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept. 2010;162(1–3):52–60.CrossRefPubMed
36.
Eissele R, Anlauf M, Schafer MK, Eiden LE, Arnold R, Weihe E. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach. Digestion. 1999;60(5):428–39.CrossRefPubMed
37.
Kidd M, Modlin IM, Bodei L, Drozdov I. Decoding the molecular and mutational ambiguities of gastroenteropancreatic neuroendocrine neoplasm pathobiology. Cell Mol Gastroenterol Hepatol. 2015;1(2):131–53.CrossRefPubMedPubMedCentral
38.
• Vigen RA, Kidd M, Modlin IM, Chen D, Zhao CM. Ultrastructure of ECL cells in Mastomys after long-term treatment with H2 receptor antagonist loxtidine. Med Mol Morphol. 2012;45(2):80–5. Evidence that acid suppression in an outbred rodent model results in G-NETs. CrossRefPubMed
39.
Betton GR, Dormer CS, Wells T, Pert P, Price CA, Buckley P. Gastric ECL-cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK&F 93479 and oxmetidine and omeprazole. Toxicol Pathol. 1988;16(2):288–98.CrossRefPubMed
40.
Cavalcoli F, Zilli A, Conte D, Ciafardini C, Massironi S. Gastric neuroendocrine neoplasms and proton pump inhibitors: fact or coincidence? Scand J Gastroenterol. 2015;50(11):1397–403.CrossRefPubMed
41.
Ko Y, Tang J, Sanagapalli S, Kim BS, Leong RW. Safety of proton pump inhibitors and risk of gastric cancers: review of literature and pathophysiological mechanisms. Expert Opin Drug Saf. 2016;15(1):53–63.CrossRefPubMed
42.
Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014;12:CD010623.
43.
Tsukamoto H, Mizoshita T, Sasaki M, Mizushima T, Tanida S, Ozeki K, et al. Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach. Asian Pac J Cancer Prev. 2011;12(4):1049–54.PubMed
44.
Cao L, Mizoshita T, Tsukamoto T, Takenaka Y, Toyoda T, Cao X, et al. Development of carcinoid tumors of the glandular stomach and effects of eradication in Helicobacter pylori-infected Mongolian gerbils. Asian Pac J Cancer Prev. 2008;9(1):25–30.PubMed
45.
La Rosa S, Chiaravalli AM, Capella C, Uccella S, Sessa F. Immunohistochemical localization of acidic fibroblast growth factor in normal human enterochromaffin cells and related gastrointestinal tumours. Virchows Arch. 1997;430(2):117–24.CrossRefPubMed
46.
Mahr S, Neumayer N, Kolb HJ, Schepp W, Classen M, Prinz C. Growth factor effects on apoptosis of rat gastric enterochromaffin-like cells. Endocrinology. 1998;139(10):4380–90.CrossRefPubMed
47.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997;6(7):1169–75.CrossRefPubMed
48.
Giusti F, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA)1993.
49.
Dreijerink KM, Hoppener JW, Timmers HM, Lips CJ. Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation. Nat Clin Pract Endocrinol Metab. 2006;2(10):562–70.CrossRefPubMed
50.
Ito T, Igarashi H, Uehara H, Berna MJ, Jensen RT. Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Medicine (Baltimore). 2013;92(3):135–81.CrossRef
51.
• Bonnavion R, Teinturier R, Jaafar R, Ripoche D, Leteurtre E, Chen YJ, et al. Islet cells serve as cells of origin of pancreatic gastrin-positive endocrine tumors. Mol Cell Biol. 2015;35(19):3274–83. Men1 deletion is sufficent for pancreatic gastrinomas. CrossRefPubMedPubMedCentral
52.
Suissa Y, Magenheim J, Stolovich-Rain M, Hija A, Collombat P, Mansouri A, et al. Gastrin: a distinct fate of neurogenin3 positive progenitor cells in the embryonic pancreas. PLoS One. 2013;8(8):e70397.CrossRefPubMedPubMedCentral
53.
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199–203.CrossRefPubMedPubMedCentral
54.
Anlauf M, Perren A, Henopp T, Rudolf T, Garbrecht N, Schmitt A, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut. 2007;56(5):637–44.CrossRefPubMedPubMedCentral
55.
Wang EH, Ebrahimi SA, Wu AY, Kashefi C, Passaro E Jr, Sawicki MP. Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res. 1998;58(19):4417–20.PubMed
56.
Krause WJ. Brunner’s glands: a structural, histochemical and pathological profile. Prog Histochem Cytochem. 2000;35(4):259–367.CrossRefPubMed
57.
Krause WJ, Leeson CR. The origin, development and differentiation of Brunner’s glands in the rat. J Anat. 1967;101(Pt 2):309–20.PubMedPubMedCentral
58.
Ahnen DJ, Poulsom R, Stamp GW, Elia G, Pike C, Jeffery R, et al. The ulceration-associated cell lineage (UACL) reiterates the Brunner's gland differentiation programme but acquires the proliferative organization of the gastric gland. J Pathol. 1994;173(4):317–26.CrossRefPubMed
59.
Montaner B, Asbert M, Perez-Tomas R. Immunolocalization of transforming growth factor-alpha and epidermal growth factor receptor in the rat gastroduodenal area. Dig Dis Sci. 1999;44(7):1408–16.CrossRefPubMed
60.
Wang Y, Shi C, Lu Y, Poulin EJ, Franklin JL, Coffey RJ. Loss of Lrig1 leads to expansion of Brunner glands followed by duodenal adenomas with gastric metaplasia. Am J Pathol. 2015;185(4):1123–34.CrossRefPubMedPubMedCentral
61.
Evers BM, Rady PL, Sandoval K, Arany I, Tyring SK, Sanchez RL, et al. Gastrinomas demonstrate amplification of the HER-2/neu proto-oncogene. Ann Surg. 1994;219(6):596–601.CrossRefPubMedPubMedCentral
62.
Goebel SU, Iwamoto M, Raffeld M, Gibril F, Hou W, Serrano J, et al. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res. 2002;62(13):3702–10.PubMed
63.
MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyerson M. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res. 2006;4(10):793–801.CrossRefPubMed
64.
Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I, Tsukada T. Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Mol Cell Biol. 2004;24(15):6569–80.CrossRefPubMedPubMedCentral
65.
La P, Desmond A, Hou Z, Silva AC, Schnepp RW, Hua X. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene. 2006;25(25):3537–46.CrossRefPubMed
66.
Canaff L, Vanbellinghen JF, Kanazawa I, Kwak H, Garfield N, Vautour L, et al. Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. J Clin Endocrinol Metab. 2012;97(2):E282–91.CrossRefPubMed
67.
Nagamura Y, Yamazaki M, Shimazu S, Tsukada T, Sakurai A. Application of an intracellular stability test of a novel missense menin mutant to the diagnosis of multiple endocrine neoplasia type 1. Endocr J. 2012;59(12):1093–8.CrossRefPubMed
68.
Shimazu S, Nagamura Y, Yaguchi H, Ohkura N, Tsukada T. Correlation of mutant menin stability with clinical expression of multiple endocrine neoplasia type 1 and its incomplete forms. Cancer Sci. 2011;102(11):2097–102.CrossRefPubMed
69.
70.
Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008;286(1–2):69–74.CrossRefPubMed
71.
Cives M, Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. Curr Treat Options in Oncol. 2017;18(3):14.CrossRef
72.
Phan AT, Kunz PL, Reidy-Lagunes DL. New and emerging treatment options for gastroenteropancreatic neuroendocrine tumors. Clin Adv Hematol Oncol. 2015;13(5 Suppl 5):1–18.
73.
Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013;8(10):e76462.CrossRefPubMedPubMedCentral
74.
Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, et al. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol. 2017;83(3):466–75.CrossRefPubMed
75.
Molina-Cerrillo J, Alonso-Gordoa T, Martinez-Saez O, Grande E. Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors. Oncologist. 2016;21(6):701–7.CrossRefPubMedPubMedCentral
76.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514–23.CrossRefPubMedPubMedCentral
77.
• Chung C. Management of neuroendocrine tumors. Am J Health Syst Pharm. 2016;73(21):1729–44. Review of new clinical treatments for NETs.CrossRefPubMed
Metadata
Title
Pathophysiology of Gastric NETs: Role of Gastrin and Menin
Authors
Sinju Sundaresan
Anthony J. Kang
Juanita L. Merchant
Publication date
01-07-2017
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 7/2017
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-017-0572-y

Other articles of this Issue 7/2017

Current Gastroenterology Reports 7/2017 Go to the issue

Small Intestine (D Sachar, Section Editor)

Tropical Enteropathies

Esophagus (J Clarke and N Ahuja, Section Editors)

Surgical Anti-Reflux Options Beyond Fundoplication

Large Intestine (B Cash, Section Editor)

The Evaluation and Office Management of Hemorrhoids for the Gastroenterologist

Small Intestine (D Sachar, Section Editor)

Targeting Small Bowel Receptors to Treat Constipation and Diarrhea

Pediatric Gastroenterology (S Orenstein, Section Editor)

Improved Outcomes with an Outpatient Multidisciplinary Intensive Feeding Therapy Program Compared with Weekly Feeding Therapy to Reduce Enteral Tube Feeding Dependence in Medically Complex Young Children
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits